Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives - PubMed (original) (raw)
Clinical Trial
doi: 10.1136/gut.2008.162404. Epub 2008 Nov 5.
Affiliations
- PMID: 18987031
- DOI: 10.1136/gut.2008.162404
Clinical Trial
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
J Tack et al. Gut. 2009 Mar.
Erratum in
- Gut. 2012 Sep;61(9):1298
Abstract
Objective: To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT(4) receptor agonist, in patients with chronic constipation.
Methods: In this multicentre, randomised, placebo controlled, parallel-group, phase III study, patients with chronic constipation (two or fewer spontaneous complete bowel movements (SCBM)/week) received 2 mg or 4 mg prucalopride or placebo, once daily, for 12 weeks. The primary efficacy endpoint was the proportion of patients reaching three or more SCBM/week. The key secondary efficacy endpoint was the proportion of patients having an increase of one or more SCBM/week. The primary QOL endpoint was the patient assessment of constipation QOL satisfaction subscale score. Safety parameters included adverse events, laboratory values and cardiovascular events.
Results: Efficacy was evaluated over 713 patients. Averaged over 12 weeks, higher proportions of patients on prucalopride 2 mg (19.5%; p<0.01), 4 mg (23.6%; p<0.001) had three or more SCBM/week (or normalisation of bowel function) compared with placebo (9.6%). Similar results were seen in the subgroup (83%) of patients dissatisfied with previous laxative treatment. Both doses of prucalopride also significantly improved secondary efficacy and QOL endpoints, including the proportion of patients with an increase of one or more SCBM/week, evacuation completeness, perceived disease severity and treatment effectiveness and QOL. Prucalopride 4 mg significantly reduced the need for straining versus placebo (p<0.05). The most frequent treatment-related adverse events were headache and diarrhoea. Both doses of prucalopride were safe and well tolerated.
Conclusion: Prucalopride significantly and consistently improved bowel function, associated symptoms and satisfaction in chronically constipated patients.
Trial registration: ClinicalTrials.gov NCT00488137.
Similar articles
- Prucalopride: a review of its use in the management of chronic constipation.
Keating GM. Keating GM. Drugs. 2013 Nov;73(17):1935-50. doi: 10.1007/s40265-013-0140-1. Drugs. 2013. PMID: 24194435 Review. - Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Quigley EM, et al. Aliment Pharmacol Ther. 2009 Feb 1;29(3):315-28. doi: 10.1111/j.1365-2036.2008.03884.x. Epub 2008 Nov 8. Aliment Pharmacol Ther. 2009. PMID: 19035970 Clinical Trial. - A placebo-controlled trial of prucalopride for severe chronic constipation.
Camilleri M, Kerstens R, Rykx A, Vandeplassche L. Camilleri M, et al. N Engl J Med. 2008 May 29;358(22):2344-54. doi: 10.1056/NEJMoa0800670. N Engl J Med. 2008. PMID: 18509121 Clinical Trial. - Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment.
Cinca R, Chera D, Gruss HJ, Halphen M. Cinca R, et al. Aliment Pharmacol Ther. 2013 May;37(9):876-86. doi: 10.1111/apt.12278. Epub 2013 Mar 11. Aliment Pharmacol Ther. 2013. PMID: 23480216 Clinical Trial. - Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.
Pennant M, Orlando R, Barton P, Bayliss S, Routh K, Meads C. Pennant M, et al. Health Technol Assess. 2011 May;15 Suppl 1:43-50. doi: 10.3310/hta15suppl1/05. Health Technol Assess. 2011. PMID: 21609652 Review.
Cited by
- Prucalopride.
Frampton JE. Frampton JE. Drugs. 2009;69(17):2463-76. doi: 10.2165/11204000-000000000-00000. Drugs. 2009. PMID: 19911858 Clinical Trial. - Effectiveness of electroacupuncture versus prucalopride for women with severe chronic constipation: secondary analysis of a randomized controlled trial.
Wang X, Sun Y, Yan S, Shi H, Zhu L, Gao S, Liu Z. Wang X, et al. Int J Colorectal Dis. 2023 Jan 20;38(1):20. doi: 10.1007/s00384-023-04313-z. Int J Colorectal Dis. 2023. PMID: 36662303 Clinical Trial. - Prucalopride: a review of its use in the management of chronic constipation.
Keating GM. Keating GM. Drugs. 2013 Nov;73(17):1935-50. doi: 10.1007/s40265-013-0140-1. Drugs. 2013. PMID: 24194435 Review. - Motility: prucalopride for chronic constipation.
Bassotti G, Villanacci V. Bassotti G, et al. Nat Rev Gastroenterol Hepatol. 2009 Jun;6(6):324-5. doi: 10.1038/nrgastro.2009.81. Nat Rev Gastroenterol Hepatol. 2009. PMID: 19494821 No abstract available. - Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.
Tse Y, Armstrong D, Andrews CN, Bitton A, Bressler B, Marshall J, Liu LW. Tse Y, et al. Can J Gastroenterol Hepatol. 2017;2017:8612189. doi: 10.1155/2017/8612189. Epub 2017 Feb 8. Can J Gastroenterol Hepatol. 2017. PMID: 28271055 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical